NCT06734065Recruiting
Effect of Non-Invasive Lung Fluid Monitoring for Heart Failure Management in Primary Care
Effect of Non-Invasive Lung Fluid Monitoring Using ReDS Technology for Heart Failure Management in Primary Care Settings: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 27 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Remote dielectric sensing (ReDS) technology offers a non-invasive method for assessing lung congestion. This randomized controlled trial aims to evaluate the effectiveness and processes of the ReDS-guided heart failure management program in primary care settings for patients with heart failure.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- First submitted
- 27 Nov 2024
- Start date
- 16 Apr 2025
- Primary completion date
- Jul 2030
- Lead sponsor
- Linkoeping University
- Diseases
- Heart failure
- NCT number
- NCT06734065
What you commit to
- Study type: Interventional
- Planned participants: 330
- From 16 Apr 2025 to the primary completion date, Jul 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Implantation of a left ventricular assist device or cardiac transplantation.
Other
- NYHA I
- Life expectancy \<6 months
- Physical characteristics that prevented use of the ReDS (body mass index \< 22 or \>39, and height less than 155 cm or higher than 195 cm)
Who the study is looking for
- Age ≥ 18 years, there is no upper age limit
- Diagnosed with heart failure regardless of left ventricular ejection fraction
- Having New York Heart Association (NYHA) Class III/IV irrespective of prior hospitalisation for heart failure, or NYHA II with a history of at least one hospitalisation for heart failure within the previous 12 months
- Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) within 12 months: (a) ≥450 pg/ml for patients under 50 years; (b) ≥900 pg/ml for patients aged 50-75 years; (c) ≥1800 pg/ml for patients over 75 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Primary care center Centrum Flen Coordinator of this site? Confirm its status | Flen | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.